We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Xi'an Tianlong Science & Technology Co., Ltd

Tianlong is an innovative, high-technology company that provides professional PCR detection devices, reagent kits and... read more Featured Products: More products

Download Mobile App




Tianlong Showcases Latest Real-Time PCR System and Innovative Molecular Diagnostic Solutions at MEDICA 2023

By LabMedica International staff writers
Posted on 29 Nov 2023
Print article
Image: TianLong Science and Technology Co., Ltd. is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023 (Photo courtesy of TianLong)
Image: TianLong Science and Technology Co., Ltd. is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023 (Photo courtesy of TianLong)
TianLong Science and Technology Co., Ltd. (Shaanxi, China) is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023.

MEDICA in Düsseldorf, a leading medical B2B trade fair, has once again become a global highlight from 13-16 November this year. Tianlong Technology made its appearance at this grand event, in collaboration with Kehua Bio-engineering, showcasing the latest IVD solutions to the global market.

TianLong participated in MEDICA 2023 with excellent products and solutions including iGeneCase 1600 Diagnostics-in-a-Suitcase, Panall 8000 all-in-one molecular diagnosis system, and PANA 9600X Automated Nucleic Acid Workstation, as well as a variety of nucleic acid extraction systems and PCR systems, supporting lab detection in automation, informatics, and intelligence.

The nucleic acid extraction and PCR testing reagents cover the detection of various common diseases, meeting the detection needs in clinical diagnosis, epidemic monitoring, food safety, forensic identification, scientific research, etc.

During the event, Tianlong engaged in insights exchanges and cooperative discussions with experts, scholars, as well as companies from around the world, and also presented visitors with pioneering technologies and innovative products, as well as the latest research achievements and application cases in molecular diagnostics.

Thanks to the participation in MEDICA 2023, Tianlong has gained valuable experience and feedback, enhanced market influence, and expanded international cooperation opportunities. In the future, Tianlong will continue to develop research and development efforts and innovations in the medical industry.

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.